United States set
Menu Shopping cart $0 Search
Manufactured by BioVendor

Granulysin Human, Sheep Polyclonal Antibody

  • Regulatory status:RUO
  • Type:Polyclonal Antibody
  • Other names:Lymphokine LAG-2, T-cell activation protein 519, GNLY, LAG2, NKG5, TLA519
  • Species:Human
Cat. No. Size Price
1 pc / 2 - 5 pcs / 6+ pcs

RD184327100 0.1 mg $277 / $243 / On request
PubMed Product Details
Technical Data


Polyclonal Antibody



Source of Antigen

E. coli




The antibody was raised in sheep by immunization with the recombinant Human Granulysin.

Amino Acid Sequence

The immunization antigen (15.33 kDa) is a protein containing 133 AA of recombinant Human Granulysin. N-terminal His-tag, 10 extra AA.


Species Reactivity


Purification Method

Immunoaffinity chromatography on a column with immobilized recombinant Human Granulysin.

Antibody Content

0.1 mg (determined by BCA method, BSA was used as a standard)


The antibody is lyophilized in 0.05 M phosphate buffer, 0.1 M NaCl, pH 7.2. 


Add 0.2 ml of deionized water and let the lyophilized pellet dissolve completely. Slight turbidity may occur after reconstitution, which does not affect activity of the antibody. In this case clarify the solution by centrifugation.


At ambient temperature. Upon receipt, store the product at the temperature recommended below.


The lyophilized antibody remains stable and fully active until the expiry date when stored at -20°C. Aliquot the product after reconstitution to avoid repeated freezing/thawing cycles and store frozen at -80°C. Reconstituted antibody can be stored at 4°C for a limited period of time; it does not show decline in activity after one week at 4°C.

Quality Control Test

Indirect ELISA – to determine titer of the antibody SDS PAGE – to determine purity of the antibody BCA - to determine quantity of the antibody


Research topic

Immune Response, Infection and Inflammation, Oncology, Transplantation


Granulysin was first identified by subtractive hybridization in a search for genes expressed by human T lymphocytes ‘late’ (3– 5 days) after activation. Granulysin is a product of protein-coding gene with the same name – Granulysin, composed of 5 exons. This protein is a member of the saposin-like protein family (SAPLIP) which contain a saposin B-type domain. A single mRNA is translated into 15 kDa granulysin, some of which is processed at both the amino and carboxy termini to a 9 kDa protein. The two molecules differ in their roles in immune responses and cell localization. The 9 kDa form is sequestered in cytolytic granules and rapidly released after degranulation, while the 15 kDa form is constitutively secreted. Both isoform induce expression of proinflammatory cytokines, act as chemoattractants or alarmins and activate immature dendritic cells (iDC). Studies with recombinant 9 kDa granulysin have demonstrated its cytolytic and proinflammatory properties. 9 kDa granulysin is contained in the cytotoxic granules of cytolytic T-cells (CTLs) and natural killers (NKs) and it is directionally released following target cell recognition. This isoform is proinflammatory and has a broad cytotoxic spectrum against gram-negative and gram-positive bacteria, fungi, yeast, parasites and tumors. Granulysin contributes to apoptosis of cancer cells via Cytochrome C. Granulysin directly kills Mycobacterium tuberculosis and is involved in host defence against leprosy. Recombinant 9 kDa granulysin is dependent on perforin for killing intracellular pathogens. Perforin and granzyme B are colocalized with 9 kDa granulysin. Granulysin is an important mediator of damage in a variety of skin diseases, including folliculitis, psoriasis, acne, lichen planus and viral vesicles. Recent data also suggest that granulysin may be useful as a diagnostic and therapeutic agent in clinical cancer. Granulysin expression has been widely correlated with positive prognosis in variety of cancers. Progression of cancer was associated with decreased granulysin expression in peripheral NK cells in comparison to controls and tumor-free patients. Granulysin is suggested to be a potential biomarker in transplantation; its level increases in severity of graft vs host disease (GVHD). In contrast, 15 kDa granulysin is located in distinct granules negative for perforin and granzyme B and these are released by activated cytolytic cells. The larger isoform is not cytotoxic, but plays an important role in differentiation of monocytes to dendritic cells. Further, 15 kDa granulysin activates both murine and human iDC. Granulysin binds to and increases permeability of a target cell’s plasma membrane resulting in a flux of calcium and potassium. Blocking this ion flux protects cells from lysis. The granulysin-mediated increase of intracellular calcium could contribute to mitochondrial damage and induction of apoptosis. Indeed, granulysin has been shown to damage the mitochondrial membrane in the presence of calcium, and cause the release of cytochrome C and production of reactive oxygen species, and in addition to inducing the permeability of lysosomal membranes. It also may induce damage of the endoplasmic reticulum in a caspase 7-dependent manner and contribute to the activation of caspase 3. No specific receptor for granulysin has been identified to date, however, granulysin has been postulated to activate a G-coupled protein receptor and TLR4 (Toll-like receptor 4), at least in a mouse model. Because mice do not express granulysin or an apparent homologue, transgenic mice for human granulysin must be created to establish in vivo activity. In vivo, mice expressing granulysin show markedly improved anti-tumor responses, with an increased numbers of activated dendritic cells and cytokine-producing T cells. Current knowledge suggests that the distinct functions of granulysin isoforms have major implications for diagnosis and potential new therapies for human disease.

Summary References (13)

References to Granulysin

  • Clayberger C, Finn MW, Wang T, Saini R, Wilson C, Barr VA, Sabatino M, Castiello L, Stroncek D, Krensky AM. 15 kDa granulysin causes differentiation of monocytes to dendritic cells but lacks cytotoxic activity. J Immunol. 2012 Jun 15;188 (12):6119-26
  • Clayberger C, Krensky AM. Granulysin. Curr Opin Immunol. 2003 Oct;15 (5):560-5
  • Hanson DA, Kaspar AA, Poulain FR, Krensky AM. Biosynthesis of granulysin, a novel cytolytic molecule. Mol Immunol. 1999 May;36 (7):413-22
  • Houchins JP, Kricek F, Chujor CS, Heise CP, Yabe T, McSherry C, Bach FH. Genomic structure of NKG5, a human NK and T cell-specific activation gene. Immunogenetics. 1993;37 (2):102-7
  • Huang LP, Lyu SC, Clayberger C, Krensky AM. Granulysin-mediated tumor rejection in transgenic mice. J Immunol. 2007 Jan 1;178 (1):77-84
  • Jongstra J, Schall TJ, Dyer BJ, Clayberger C, Jorgensen J, Davis MM, Krensky AM. The isolation and sequence of a novel gene from a human functional T cell line. J Exp Med. 1987 Mar 1;165 (3):601-14
  • Krensky AM, Clayberger C. Biology and clinical relevance of granulysin. Tissue Antigens. 2009 Mar;73 (3):193-8
  • Krzewski K, Coligan JE. Human NK cell lytic granules and regulation of their exocytosis. Front Immunol. 2012;3:335
  • Nagasawa M, Isoda T, Itoh S, Kajiwara M, Morio T, Shimizu N, Ogawa K, Nagata K, Nakamura M, Mizutani S. Analysis of serum granulysin in patients with hematopoietic stem-cell transplantation: its usefulness as a marker of graft-versus-host reaction. Am J Hematol. 2006 May;81 (5):340-8
  • Ogawa K, Takamori Y, Suzuki K, Nagasawa M, Takano S, Kasahara Y, Nakamura Y, Kondo S, Sugamura K, Nakamura M, Nagata K. Granulysin in human serum as a marker of cell-mediated immunity. Eur J Immunol. 2003 Jul;33 (7):1925-33
  • Ono S, Otsuka A, Yamamoto Y, Kataoka TR, Koyanagi I, Miyachi Y, Kabashima K. Serum granulysin as a possible key marker of the activity of alopecia areata. J Dermatol Sci. 2014 Jan;73 (1):74-9
  • Pitabut N, Sakurada S, Tanaka T, Ridruechai C, Tanuma J, Aoki T, Kantipong P, Piyaworawong S, Kobayashi N, Dhepakson P, Yanai H, Yamada N, Oka S, Okada M, Khusmith S, Keicho N. Potential function of granulysin, other related effector molecules and lymphocyte subsets in patients with TB and HIV/TB coinfection. Int J Med Sci. 2013;10 (8):1003-14
  • Sekiguchi N, Asano N, Ito T, Momose K, Momose M, Ishida F. Elevated serum granulysin and its clinical relevance in mature NK-cell neoplasms. Int J Hematol. 2012 Oct;96 (4):461-8
Related Products Docs